IL-6 Blockade in Cytokine Storm Syndromes

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2024 Aug 8

PMID 39117839

Authors

David Barrett

Affiliations

Soon will be listed here.

Abstract

Interleukin-6 (IL-6) is a pro-inflammatory cytokine elevated in cytokine storm syndromes, including hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS). It is also elevated in cytokine release syndrome (CRS) after immune activating cancer therapies such as chimeric antigen receptor (CAR) T-cells or bispecific T-cell engagers (BITEs) and in some patients after infection with SARS-CoV-2. The interaction of IL-6 with its receptor complex can happen in several forms, making effectively blocking this cytokine's effects clinically challenging. Fortunately, effective clinical agents targeting the IL-6 receptor (tocilizumab) and IL-6 directly (siltuximab) have been developed and are approved for use in humans. IL-6 blockade has now been used to safely and effectively treat several cytokine storm syndromes (CSS). Other methods of investigation in effective IL-6 blockade are underway.

Citing Articles

Whole-body cryotherapy can reduce the inflammatory response in humans: a meta-analysis based on 11 randomized controlled trials.

He J, Zhang X, Ge Z, Shi J, Guo S, Chen J Sci Rep. 2025; 15(1):7759.

PMID: 40044835 PMC: 11882895. DOI: 10.1038/s41598-025-90396-3.

Comparison between traditional logistic regression and machine learning for predicting mortality in adult sepsis patients.

Wu H, Liao B, Ji T, Ma K, Luo Y, Zhang S Front Med (Lausanne). 2025; 11():1496869.

PMID: 39835102 PMC: 11743956. DOI: 10.3389/fmed.2024.1496869.

Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers.

Blay J, Brahmi M, Dufresne A, Swalduz A, Avrillon V, Assaad S ESMO Open. 2025; 10(1):104088.

PMID: 39754984 PMC: 11758126. DOI: 10.1016/j.esmoop.2024.104088.

Anti-Inflammatory Action and Molecular Mechanism of Fucoidan Against Cystitis Glandularis.

Chen Q, Mo J, Li Y, Gao L, Wu K Food Sci Nutr. 2024; 12(12):10255-10261.

PMID: 39723046 PMC: 11666824. DOI: 10.1002/fsn3.4560.

References

Kishimoto T, Akira S, Narazaki M, Taga T . Interleukin-6 family of cytokines and gp130. Blood. 1995; 86(4):1243-54. View

Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu K . Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A. 1985; 82(16):5490-4. PMC: 391148. DOI: 10.1073/pnas.82.16.5490. View

Shabo Y, Lotem J, Rubinstein M, Revel M, Clark S, Wolf S . The myeloid blood cell differentiation-inducing protein MGI-2A is interleukin-6. Blood. 1988; 72(6):2070-3. View

Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B . Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science. 1988; 241(4867):825-8. DOI: 10.1126/science.3136546. View

Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T . Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989; 58(3):573-81. DOI: 10.1016/0092-8674(89)90438-8. View

Lacroix M, Rousseau F, Guilhot F, Malinge P, Magistrelli G, Herren S . Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex. J Biol Chem. 2015; 290(45):26943-26953. PMC: 4646397. DOI: 10.1074/jbc.M115.682138. View

Schumacher N, Meyer D, Mauermann A, von der Heyde J, Wolf J, Schwarz J . Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles. J Biol Chem. 2015; 290(43):26059-71. PMC: 4646259. DOI: 10.1074/jbc.M115.649509. View

Imashuku S, Hibi S, Fujiwara F, Todo S . Hyper-interleukin (IL)-6-naemia in haemophagocytic lymphohistiocytosis. Br J Haematol. 1996; 93(4):803-7. DOI: 10.1046/j.1365-2141.1996.d01-1727.x. View

Imashuku S, Hibi S, Tabata Y, Sako M, Sekine Y, Hirayama K . Biomarker and morphological characteristics of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis. Med Pediatr Oncol. 1998; 31(3):131-7. DOI: 10.1002/(sici)1096-911x(199809)31:3<131::aid-mpo1>3.0.co;2-c. View

10.

Xu X, Tang Y, Song H, Yang S, Xu W, Zhao N . Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr. 2012; 160(6):984-90.e1. DOI: 10.1016/j.jpeds.2011.11.046. View

11.

Yang S, Xu X, Tang Y, Song H, Xu W, Zhao F . Associations between inflammatory cytokines and organ damage in pediatric patients with hemophagocytic lymphohistiocytosis. Cytokine. 2016; 85:14-7. DOI: 10.1016/j.cyto.2016.05.022. View

12.

Shimizu M, Nakagishi Y, Kasai K, Yamasaki Y, Miyoshi M, Takei S . Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012; 58(2):287-94. DOI: 10.1016/j.cyto.2012.02.006. View

13.

Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N . Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol. 2014; 41(4):759-67. DOI: 10.3899/jrheum.130690. View

14.

Schulert G, Minoia F, Bohnsack J, Cron R, Hashad S, Kone-Paut I . Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2017; 70(3):409-419. DOI: 10.1002/acr.23277. View

15.

Rios-Fernandez R, Callejas-Rubio J, Garcia-Rodriguez S, Sancho J, Zubiaur M, Ortego-Centeno N . Tocilizumab as an Adjuvant Therapy for Hemophagocytic Lymphohistiocytosis Associated With Visceral Leishmaniasis. Am J Ther. 2015; 23(5):e1193-6. DOI: 10.1097/MJT.0000000000000035. View

16.

Teachey D, Rheingold S, Maude S, Zugmaier G, Barrett D, Seif A . Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013; 121(26):5154-7. PMC: 4123427. DOI: 10.1182/blood-2013-02-485623. View

17.

Grupp S, Kalos M, Barrett D, Aplenc R, Porter D, Rheingold S . Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16):1509-1518. PMC: 4058440. DOI: 10.1056/NEJMoa1215134. View

18.

Topp M, Gokbuget N, Zugmaier G, Degenhard E, Goebeler M, Klinger M . Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012; 120(26):5185-7. DOI: 10.1182/blood-2012-07-441030. View

19.

Brudno J, Kochenderfer J . Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016; 127(26):3321-30. PMC: 4929924. DOI: 10.1182/blood-2016-04-703751. View

20.

Frey N, Porter D . Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016; 2016(1):567-572. PMC: 6142489. DOI: 10.1182/asheducation-2016.1.567. View